Nova Safo is a Marketplace correspondent covering a wide range of topics with a focus on macroeconomic developments here and abroad.

Nova Ltd. (NVMI) reports record-breaking 2024 results with 30% revenue growth, advanced packaging success, and strong 2025 guidance.

Received overwhelming shareholder support in favour of take-private transaction with AditxtAdvanced key pipeline programs, engaged regulatory ...

Benchmark analyst Mark Miller raised the firm’s price target on Nova (NVMI) to $295 from $245 and keeps a Buy rating on the shares, stating ...

Reese Allen came to the Bearcats at the Trade Deadline last year from the Miramichi Timberwolves. The Sydney native, now a ...

(Premiering February 12, 2025 at 9 pm on PBS) National Corporate funding for NOVA is provided by Carlisle Companies. Major funding for NOVA is provided by the NOVA Science Trust, the Corporation ...

From revenue to R&D investment, Novo and Lilly and their mega-blockbuster weight loss drugs Zepbound and Wegovy have moved ...

DOC Pharma strengthens its offerings with the acquisition of the Geopharma nutraceuticals portfolio, and the closing of the previously announced acquisition of Muscoril® New brand identity ...

MILAN, Feb. 12, 2025 /PRNewswire/ -- DOC, an Italian pharmaceutical company specialized in the marketing of generic drugs, expands its strategy by broadening its business lines and defines a new ...

- Expected use of approximately $25 million in first quarter of 2025 intended to preserve approximately 200,000 ADSs held as treasury shares COPENHAGEN, Denmark, Feb. 12, 2025 (GLOBE NEWSWIRE) -- ...

Ascendis, Ascendis Pharma, the Ascendis Pharma logo, the company logo, TransCon, SKYTROFA®, and YORVIPATH® are trademarks owned by the Ascendis Pharma group.